Home|Journals|Articles by Year|Audio Abstracts

Case Series

Artisanal cannabidiol as adjunct treatment for refractory epilepsy: A Brazilian experience

Luiz Fernando Fonseca, Karina Soares Loutfi, Clara Gontijo Camelo, José Humberto Santos Soares, Paula Carvalho Ribeiro, Raquel Machado Tófani, Bárbara Campos Mattos.

Cited by 0 Articles

Introduction: The treatment of refractory epilepsy in childhood is a challenge in medical practice. The authors describe the experience with cannabidiol (CBD) use in patients with refractory epilepsy. Objectives: To evaluate the response to CBD treatment in the control of epileptic seizures, as well as their tolerability and side effects. Methods: A retrospective descriptive, series of cases study was performed, with data collected from 24 patients aged 1 to 45 years, diagnosed with refractory epilepsy, and who used CBD as adjunctive therapy. The CBD dose used ranged from 2.5mg/kg/day to 14mg/kg/day, with an average of 6.3mg/kg/day. Results: Of the twenty four patients analyzed, there was a reduction in seizure frequency in 19 patients (79.2%), and of these, five patients (20.8%) presented seizure reduction between 50-79% (moderate response), ten patients (41.6%) presented seizure reduction between 80-99% (marked response) and four patients (16.6%) presented complete seizure resolution. On the other hand, five patients (20.8%) did not respond to CBD treatment. Of these, one patient had no change in seizure pattern and four patients (16.6%) had increased seizure frequency. Among the positive aspects of the use of CBD were reduction in the number of hospitalizations, reduction in polytherapy (70% of cases) and improvement in some cognitive and behavioral aspects. The adverse effects mentioned were considered mild. Conclusion: CBD represents a promising alternative in refractory patients to conventional anticonvulsants

Key words: Anticonvulsants, Cannabidiol, Cannabis sativa, Epilepsy, Pharmacological Treatment

Full-text options

Share this Article

Online Article Submission
• ejmanager.com

ejPort - eJManager.com
Refer & Earn
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.